Pivotal and Palobiofarma collaborate on a novel mechanism of action oral treatment in Asthma
- New collaboration aims to further accelerate the delivery of investigational treatments for Asthma
- Collaboration will enhance European patients access to novel oral asthma therapies and to explore new mechanisms of actions
Madrid, Spain. 11 September, 2018 - Pivotal and Palobiofarma announced today a new strategic collaboration to expand access of patients to novel therapies in asthma.
Asthma is a chronic respiratory disease characterised by airway inflammation and affecting all age groups. Its prevalence is increasing in many countries, especially among children. The prevalence of asthma in 2014 among the Spanish population was about 5%, of which 10% were diagnosed with severe asthma. Estimated current prevalence of asthma in European countries among adults aged between 18 and 44 years varies between 3-10%. The rates of disease tend to be higher in Northern and Western European countries where the prevalence may be higher than 10%. The long term goals of asthma management are to achieve a good control of symptoms, maintain normal activity levels of the subject with asthma, and minimise future risk of exacerbations. Current treatment of asthma usually follows a control-based approach where patients are identified for a change in asthma treatment on the basis of a poor control of symptoms or the presence of a low lung function or frequent exacerbations. Although therapeutic advances have facilitated the management of the disease, a significant proportion of asthma patients suffer from severe disease, refractory to current therapies.
Adenosine is considered an important signalling molecule in human asthma, with a function in both the acute bronchoconstrictor and airway inflammatory responses. PBF-680 is an oral adenosine A1 receptor antagonist that has successfully completed single dose escalation and treatment-period phase-I trials in healthy volunteers, plus a crossover, proof-of-concept Phase-IIa trial in mild and moderate asthma patients, in whom a single dose significantly attenuated airway hyperresponsiveness to AMP challenge and increased 8-hour post-challenge on Forced Expiratory Volume in 1 second (FEV1).
“The combined expertise in drug development and clinical research excellence of Palobiofarma and Pivotal will enable us to accelerate research and provide access to novel investigational agents,” said Dr José Javier García, MD, VP Data Management and Biostatistics at Pivotal, “We look forward to impacting positively the lives of people facing asthma throughout Europe.”
The trial is a phase II, double-blind, randomised, parallel-group, placebo controlled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on FEV1 in patients with mild-to-moderate persistent atopic asthma. The trial will be performed in 9 sites to recruit 78 patients. The primary objective of this trial is to demonstrate an improvement in FEV1 after a 15-day treatment with PBF-680 compared to placebo in mild-to-moderate asthma patients. Secondary objectives include assessment of FEV1, Area Under the Curve (AUC), evaluations on pre- and post-bronchodilator FEV1, and Patient Reported Outcomes (PROs), including Asthma Control Questionnaire-7 (ACQ-7) and Standardised Asthma Quality of Life Questionnaire (AQLQ(S)).
"We are very excited with the initiation of this phase II study with PBF-680 in asthma. This is the second phase II trial analysing efficacy outcomes of PBF-680 in mild to moderate asthma patients, following the supportive data from the proof-of-concept trial on the effect of PBF-680 on airway hyperresponsiveness to adenosine monophasphate (AMP)," said Dr. Julio Castro, Chief Executive Officer at Palobiofarma, "This study represents another cornerstone in Palobiofarma efforts to explore the potential of adenosine modulators for the treatment of inflammatory diseases like asthma.”
Pivotal was founded in 2001 by Dr. Ibrahim Farr on the principle that strategic medical advice and support should be the backbone of all clinical trials. After working for over two decades in the pharmaceutical industry, Dr. Farr recognised the need for a medium-sized CRO with a solid internal medical franchise that could act not only as the "doers" but also as the “co-thinkers” for their clients, through its strategic scientific advice. To date, we are the trusted adviser and counsellor for many companies to deliver maximum value in their drug development programmes. We are a leading privately-held European CRO and, since inception, we have experienced a fast and steady organic growth in Europe.
Pivotal's clients’ portfolio spans major pharmaceutical, biotechnological, medical device and nutrition companies, as well as independent investigators and cooperative groups. We have long-standing relations with over 190 clients. Pivotal has extensive experience across major therapeutic areas and phases I to IV. Our highly customised teams bring to each client a combination of broad industry knowledge and operational excellence, to offer our clients fresh perspectives and breakthrough business insights. Additionally, we have built a strong oncology, innovative therapies, rare diseases and early phases hub that enables us to tackle our customers most difficult challenges, turning recommendations into concrete actions. By remaining true to our core principles and values, our vision is to become our client’s preferred outsourcing solution partner.
For more information, please visit www.pivotal.es.
Palobiofarma is a clinical-stage biotechnology company specialised in the discovery and development of adenosine receptor modulators for the treatment of cancer and inflammatory diseases such as asthma and ulcerative colitis. The company exhibit one of the most attractive and diversified pipeline of first in class drugs, including three different compounds entering Phase 2 trial for Asthma/COPD, Oncology, Ulcerative Colitis, and four additional compounds in Phase I targeting Pulmonary Fibrosis, Psoriasis and NASH. Palobiofarma is focused on the development and commercialisation of novel medicines to improve people's lives.
For more information, please visit www.palobiofarma.com
Ms. Natalia Farr
M.: +34 679 488 022